Adjuvant Keytruda provides higher QoL than standard of care immunotherapy in melanoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Patients with high-risk stage III-IV melanoma who received Keytruda (pembrolizumab) after surgery reported a better quality of life than patients who received the previous standard-of-care treatment with either ipilimumab or high-dose interferon, according to a large clinical trial led by the SWOG Cancer Research Network.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents


FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for Keytruda (pembrolizumab) in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) as treatment with definitive intent for newly diagnosed patients with high-risk, locally advanced cervical cancer. 
Follow-up results from the phase Ib/II CHRYSALIS-2 study cohort evaluating the safety and tolerability of the combination of Rybrevant (amivantamab-vmjw)—a bispecific antibody targeting epidermal growth factor receptor and mesenchymal-epithelial transition—with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor, plus platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer and EGFR mutations, showed that the drug combination led to durable progression-free survival. 
Patient-reported outcomes data from the phase III NATALEE trial, presented at the European Society for Medical Oncology Virtual Plenary, show that a broad population of patients with stage 2 and 3 hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer maintained health-related quality of life during treatment with Kisqali (ribociclib) plus endocrine therapy.